Cancer - Cancer Biology - Research Scientist Faculty

Join Cedars-Sinai Cancer during a transformational period of growth and impact. Cedars-Sinai is a hub for biomedical research with over $200M in extramural research grant funding.  The medical center has been named to the Honor Roll in U.S. News & World Report's "Best Hospitals 2024-25" rankings, and Cedars-Sinai Cancer is currently ranked #16 nationally. Cedars-Sinai Cancer is looking for nationally recognized investigators to join our faculty in the Cancer Biology (CB) Program as we continue to grow.
We are seeking collaborative individuals with an active research program in the broad discipline of cancers. Applicants are required to have a strong track record of scholarship, evidenced by independent cancer research funding and peer-reviewed publications. As such, individuals with active research programs related to sex as a biological variable, metabolism, cancer immunology, microbiota, discovery and development are encouraged to apply.
The Cancer Biology (CB) program at Cedars-Sinai Cancer invites applications for full-time faculty members at the full, associate or assistant professor level. Academic rank is commensurate with qualifications and experience. The Cancer Biology program: 
·         Currently includes 73 program members who have expertise in basic cancer research with a strong emphasis on translational development.
·         Fosters a collaborative and multidisciplinary research environment in which members have access to exceptional, state-of-the-art core facilities and the single cell innovation center, training grants and clinical scholars' programs, developmental funds.
·         Maintains robust interaction with related research programs including the outstanding Cancer Prevention and Control and Cancer Therapeutics programs, and a formal network of hospital affiliations serving the Greater Los Angeles area.
·         Strengths include:
o    Genes on sex chromosomes that drive bladder cancer
o    Impacts of cross-sex hormone therapy on breast oncogenic pathways of transgender individuals
o    The contribution of obesity in liver cancer
o    The role of extracellular vesicles in cancer metastasis
o    The identification of biomarkers driving aggressive prostate cancer and therapeutic vulnerability
o    Utility of patient-derived induced pluripotent stem cell technology to identify contributors of cancer in high-risk populations
o    Novel mouse models of glioblastoma and other cancers driven by patient-derived mutations
o    Uncovering biological barriers to conventional therapies for the development of novel therapeutic delivery strategies.
o    Participates in the Molecular Twin Initiative and the omiCSearch are outstanding institutional resources with annotated blood and tumor biospecimens from >5,000 patients with cancer.
In addition to a large patient population within the Cedars Sinai Cancer Clinical Programs, the Greater Los Angeles and its surrounding communities comprise one of the largest and most diverse populations in the United States.  This includes Hispanic/Latinx, Filipinx, Korean, African American, Jewish American, LGBTQ and non-Hispanic White communities – each with unique cancer burdens and unaddressed cancer research needs.  As the CB program grows, priority areas for faculty recruitment are focused on identifying individuals whose research is positioned to address the immediate and future cancer needs of these communities.
 About Cedars-Sinai Cancer
At Cedars-Sinai Cancer, we offer state-of-the-art treatments, experimental therapies, next-generation research and cutting-edge clinical trials for over 60 types of cancer at more than
10 locations throughout Greater Los Angeles. Patients turn to us because they know our progress is their progress, and our strides forward are their success.
 Our rapidly expanding, vertically integrated health system is a central destination for the integration of revolutionary advances into daily clinical practice. We see over 7,600 new cancer cases each year, creating customized, coordinated care plans that fit each patient's unique needs.
About Cedars-Sinai
We are a national leader in providing high-quality, patient-centered healthcare that encompasses primary care as well as specialized medicine and conducting research that leads to lifesaving discoveries and innovations. Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the nation, setting standards in quality and innovative patient care, research, teaching, and community service. Today, Cedars-Sinai is known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare by developing new approaches to treatment and educating tomorrow's health professionals. Additionally, Cedars-Sinai demonstrates a commitment to the community through programs that improve the health of its most vulnerable residents.
At Cedars-Sinai, we are caretakers and innovators committed to the pursuit of equitable healthcare. But health equity is not possible without representation. Our commitment to diversity goes beyond demographics or checking boxes. Our people must reflect the diverse identities, experiences and geographies of the communities and patients we serve – because that's what our patients, colleagues and communities deserve.
 
Community Outreach
A commitment to meeting the community's health needs has been a defining quality of Cedars-Sinai since the beginning - from the opening of the 12-bed Kaspare Cohn Hospital in Angeleno Heights in 1902 to what is now a world-renowned, nonprofit academic medical center with 915 licensed beds.
 
Academic Research
 
Along with caring for patients, Cedars-Sinai is a hub for biomedical research and a top 10 academic medical center for NIH funding with over $230M in extramural research grant funding. As the largest academic medical center in the western United States, Cedars-Sinai is also training the next generation of physicians, researchers, and allied health professionals. Physicians and scientists at Cedars-Sinai are actively engaged in translational research to bring medical advancements directly from the laboratory to the bedside.   
Our compensation philosophyWe offer competitive total compensation that includes pay, benefits, and other incentive programs for our employees. The total pay range shown takes into account the wide range of factors that are considered in making compensation decisions including knowledge/skills; relevant experience and training; education/certifications/licensure; and other business and organizational factors. This total pay range includes any incentive payments that may be applicable to this role. We also offer a comprehensive faculty benefits package.
Pay range $130,000-290,000
 QualificationsWe invite candidates with strength in any research area broadly defined by cancer biology to apply.  
Position Requirements:
·         PhD, MD/PhD, or an MD with an accompanying experience
·         Demonstrated excellence in cancer research of high scientific impact and translation
·         A track record of peer-reviewed publications
·         Active cancer relevant peer-reviewed funding Application InstructionsPlease upload a current CV and cover letter addressed to: Sean Li, Dolores Di Vizio and Lali Medina-Kauwe, co-leads of Cancer Biology program